ReviewCurrent nutrition reports2024
Management of Cardiovascular Diseases by Short-Chain Fatty Acid Postbiotics.
Review in Current nutrition reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Decoding the Applications of Microbial Metabolites: Insights into the Antibacterial Potential of Lactobacillus acidophilus Postbiotics.Current microbiology · 2026Article
- Life-Course Programming of Kidney Disease: Roles of Gut Microbiota Dysbiosis and Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Review
- Gut Microbiota: Cardiovascular Disease Prevention and Targeted Therapies.Biomedicines · 2026Review
- Fine-Gradient Low-Molecular-Weight Hyaluronic Acid Supplementation Modulates Gut Microbial Profiles and SCFA Output in a Starch-Containing In Vitro Fecal Fermentation Model.Microorganisms · 2026Article
- The gut-heart dialogue: an epigenetic perspective on myocardial infarction.NPJ biofilms and microbiomes · 2026Review
- Scaling Up Postbiotics Production: A Prospective Review of Processes and Health Benefits.Probiotics and antimicrobial proteins · 2026Review
- A Single Key for Many Doors? Unlocking the Bio-chemical Potential of Lactobacillus bulgaricus Metabolic Postbiotic.Probiotics and antimicrobial proteins · 2026Article
- Demystifying the role of postbiotics in inflammation mediated metabolic disorders: an updated review.Food science and biotechnology · 2026Review
- Review
- Gut microbiota-derived metabolites in cardiovascular disease: mechanisms, disease-specific roles, and translational opportunities.Frontiers in cardiovascular medicine · 2026Review
- Emerging Nonthermal Technologies for the Production of Postbiotics.Comprehensive reviews in food science and food safety · 2025Review
- Early-Life Prevention of Cardiovascular-Kidney-Metabolic Syndrome: The DOHaD Perspective on Resveratrol and Short-Chain Fatty Acids.Antioxidants (Basel, Switzerland) · 2025Review
- The Role of the Gut Microbiota in Heart Failure: Pathophysiological Insights and Future Perspectives.Medicina (Kaunas, Lithuania) · 2025Review
- Beyond Cholesterol: Emerging Risk Factors in Atherosclerosis.Journal of clinical medicine · 2025Review
- Postbiotic Sodium Butyrate Mitigates Hypertension and Kidney Dysfunction in Juvenile Rats Exposed to Microplastics.Antioxidants (Basel, Switzerland) · 2025Article
- Synergistic Effect of Acupuncture and Traditional Chinese Medicine on Cerebral Infarction in Rats: Roles of Short-Chain Fatty Acids and Interleukin-17.International journal of general medicine · 2025Article
- Advances in polysaccharide-based biopolymers for probiotic encapsulation: From single polysaccharides to composite systems.Current research in food science · 2025Review
- Protective Effect of Resveratrol on Kidney Disease and Hypertension Against Microplastics Exposure in Male Juvenile Rats.Antioxidants (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewGlobal health concerns persist in the realm of cardiovascular diseases (CVDs), necessitating innovative strategies for both prevention and treatment. This narrative review aims to explore the potential of short-chain fatty acids (SCFAs)-namely, acetate, propionate, and butyrate-as agents in the realm of postbiotics for the management of CVDs. RECENT
findingsWe commence our discussion by elucidating the concept of postbiotics and their pivotal significance in mitigating various aspects of cardiovascular diseases. This review centers on a comprehensive examination of diverse SCFAs and their associated receptors, notably GPR41, GPR43, and GPR109a. In addition, we delve into the intricate cellular and pharmacological mechanisms through which these receptors operate, providing insights into their specific roles in managing cardiovascular conditions such as hypertension, atherosclerosis, heart failure, and stroke. The integration of current information in our analysis highlights the potential of both SCFAs and their receptors as a promising path for innovative therapeutic approaches in the field of cardiovascular health. The idea of postbiotics arises as an optimistic and inventive method, presenting new opportunities for preventing and treating cardiovascular diseases.
Indexed as
Identifiers
38656688What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.